Month: February 2021

SARS-CoV-2 Infection Prevented and Treated in Human Lung Tissue Model

02/13/2021

Excerpt from the Article: Given the steady numbers of new COVID-19 cases, the appearance of new variants, and the considerable time that vaccinations will take to reach target levels needed for herd immunity, the development of treatments and useful therapeutics remains a top priority. In particular, treatments and preventive approaches that can be widely and…

Read More

UHN-led study shows antiviral drug speeds up clearance of COVID-19

02/12/2021

Excerpt from the Article: A clinical study led by Dr. Jordan Feld, a liver specialist at UHN’s Toronto Centre for Liver Disease, showed an experimental antiviral drug can significantly speed up recovery for COVID-19 outpatients – patients who do not need to be hospitalized. This could become an important intervention to treat infected patients and…

Read More

Experimental stem cell therapy a potential weapon against COVID-19

02/12/2021

Excerpt from the Article: When the COVID-19 pandemic hit, researchers in Canada and around the world moved quickly to pivot their research and help with the development of new treatments and vaccines.  At The Ottawa Hospital, this resulted in more than 60 different research projects and trials, including an innovative clinical trial of mesenchymal stem…

Read More

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

02/12/2021

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) — Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines administered by tablet, today announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its oral COVID-19 tablet vaccine candidate was generally well-tolerated, and immunogenic as measured by…

Read More

NeuroRx Initiates Phase 2/3 Study of Inhaled ZYESAMI™ for Severe COVID-19 with UCI Health

02/11/2021

Excerpt from the Press Release: RADNOR, Pa. and IRVINE, Calif., Feb. 3, 2021 /PRNewswire/ — NeuroRx, Inc. today announced initiation of a Phase 2/3 clinical trial investigating the role of inhaled ZYESAMI™ (aviptadil) for the treatment of patients with Severe COVID-19 in partnership with UCI Health of the University of California, Irvine. UCI Health was…

Read More

Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting

02/10/2021

Excerpt from the Press Release: BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the Phase 2 virology trial evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting. The trial will enroll patients in…

Read More

Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19

02/09/2021

Excerpt from the Press Release: BURLINGAME, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has initiated a Phase 3 clinical trial of CPI-006 for the treatment of hospitalized patients with COVID-19. The study is expected to enroll approximately 1,000 patients at sites in…

Read More

Using MRI for prostate cancer diagnosis equals or beats current standard

02/08/2021

Excerpt from the Press Release: Toronto – (February 4, 2021) The results of a Phase III randomized clinical trial have shown that when it comes to detecting clinically significant prostate cancer, Magnetic Resonance Imaging (MRI) with targeted biopsies (MRI-TBx) matches the current standard and brings a multitude of advantages. The PRostate Evaluation for Clinically Important…

Read More

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD

02/05/2021

Excerpt from the Press Release: WATERTOWN, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the first patient has been dosed in the Phase 1 clinical trial of EYP-1901 as…

Read More

Otsuka Pharmaceutical Development & Commercialization, Inc., and Spencer Health Solutions, Inc., Enter Agreement for Use of spencer® Smart Hub in Clinical Trials and Commercial Applications

02/04/2021

Excerpt from the Press Release: PRINCETON, N.J. & MORRISVILLE, N.C.–(BUSINESS WIRE)–Otsuka Pharmaceutical Development & Commercialization, Inc., and Spencer Health Solutions, Inc., today announced an agreement to jointly create a transformational patient experience using the spencer® smart hub, the world’s first at-home medication device that connects patients and their care teams through an easy-to-use, fully integrated…

Read More